Leads Biolabs shares updated Phase II data for opamtistomig
Leads Biolabs says it released updated Phase II data for opamtistomig (LBL-024) and plans an oral presentation, describing robust responses and PFS benefits in first-line NSCLC with chemotherapy.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.